方法对比

	血管炎损伤指数 (VDI)	28关节疾病活动度评分 (DAS28)	Routine Assessment of Patient Index Data 3 (RAPID3)	系统性红斑狼疮疾病活动度指数 2000 (SLEDAI-2K)
领域	风湿病学	风湿病学	风湿病学	风湿病学
方法族	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
起源年份	2003	1995	2008	2002
提出者	Exley et al.	Prevoo et al.	Pincus et al.	Gladman et al.
类型	Clinician-rated	Clinician-rated	Patient-reported outcome (PRO)	Clinician-rated
开创性文献	Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Pusey CD, Savage CO. Development and initial validation of the Vasculitis Damage Index (VDI) for systemic vasculitis. Arthritis & Rheumatism. 2003;48(7):2146-2157.	Prevoo ML, Hart's AM, Van Houwelingen HC, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism. 1995;38(1):44-48.	Pincus T, Bergman MJ, Sokka T, Roth SH, Swearingen C, Yazici Y. Activity of rheumatoid arthritis is similar in patients seen in a primary care physician-based practice and in an academic rheumatology-based practice. Arthritis Care Research. 2008;59(9):1229-1236.	Gladman DD, Ibañez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. The Journal of Rheumatology. 2002;29(2):288-291.
别名	VDI, Vasculitis Permanent Organ Damage Score	DAS28, DAS28-CRP, DAS28-ESR	RAPID3, RAPID-3	SLEDAI, SLEDAI-2K, SLE Disease Activity Index
相关	4	3	3	3
摘要	The VDI is a clinician-assessed measure of permanent organ damage in patients with systemic vasculitis, including ANCA-associated vasculitis (AAV), polyarteritis nodosa, and other necrotising vasculitides. Introduced by Exley et al. (2003), VDI captures cumulative irreversible damage across organ systems, complementing disease activity measures (such as the Birmingham Vasculitis Activity Score). Systemic vasculitis is characterised by inflammation of blood vessel walls, leading to ischaemia and permanent tissue damage. VDI acknowledges that damage accrues over time and is largely irreversible, making it a prognostically important measure distinct from transient inflammatory activity.	The DAS28 is a composite measure of rheumatoid arthritis (RA) disease activity, combining joint counts, inflammatory markers, and patient-reported global health. Developed in 1995 by Prevoo and colleagues, it has become the gold standard for monitoring RA activity in clinical trials and practice. It integrates objective clinical signs with laboratory and subjective assessment, providing a single numerical index of disease burden.	RAPID3 is a patient-reported outcome (PRO) measure of rheumatoid arthritis disease activity based on three simple self-report items: patient-counted swollen and tender joints and overall health assessment. Introduced by Pincus et al. in 2008, RAPID3 was designed for primary care and busy practices where joint examination is impractical or time-limited. Remarkably, RAPID3 correlates strongly with clinician-examined composite measures (DAS28, CDAI, SDAI) and predicts long-term radiographic progression equally well, making it a practical alternative for resource-limited settings and self-directed monitoring.	The SLEDAI is a comprehensive clinician-assessed measure of systemic lupus erythematosus (SLE) disease activity, capturing manifestations across multiple organ systems (cutaneous, renal, neuropsychiatric, hematologic, and serological). Introduced by Bombardier et al. (1992) and refined as SLEDAI-2K by Gladman et al. (2002), SLEDAI uses weighted scoring of 24 clinical and laboratory features to quantify overall SLE activity. It is the most widely used outcome measure in SLE research and clinical trials, enabling standardised assessment of disease progression, flare prediction, and treatment response in this complex multisystem disease.